Skip to main content

Truvada FDA Approval History

FDA Approved: Yes (First approved August 2, 2004)
Brand name: Truvada
Generic name: emtricitabine and tenofovir
Dosage form: Tablets
Company: Gilead Sciences, Inc.
Treatment for: HIV Infection, Pre-Exposure Prophylaxis

Truvada (emtricitabine and tenofovir disoproxil fumarate) is a combination of nucleoside analog HIV-1 reverse transcriptase inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection, and for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in people at high risk.

Development timeline for Truvada

DateArticle
May  9, 2019Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic
May 15, 2018Approval FDA Approves Expanded Indication for Truvada (emtricitabine and tenofovir disoproxil fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
Jul 16, 2012Approval FDA Approves Truvada for Reducing the Risk of Sexually Acquired HIV Infection
Aug  2, 2004Approval Truvada Gilead Sciences, Inc. - Treatment for HIV Infection
May 17, 2004U.S. FDA Grants Priority Review to Gilead's Fixed Dose Co-Formulation of Viread and Emtriva for HIV
Mar 15, 2004Gilead Submits Applications to U.S. and European Regulatory Authorities for Fixed Dose Co-Formulation of Viread and Emtriva

See also

Truvada (emtricitabine and tenofovir) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer